Annual Operating Profit
-$282.18 M
+$502.90 M+64.06%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual operaing income is currently -$282.18 million, with the most recent change of +$502.90 million (+64.06%) on 31 December 2023. During the last 3 years, it has risen by +$546.26 million (+65.94%). ALNY annual operating profit is now -6583.44% below its all-time high of -$4.22 million, reached on 31 December 2002.ALNY Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$76.91 M
-$125.52 M-258.20%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly operating income is currently -$76.91 million, with the most recent change of -$125.52 million (-258.20%) on 30 September 2024. Over the past year, it has dropped by -$290.77 million (-135.96%). ALNY quarterly operating profit is now -135.96% below its all-time high of $213.87 million, reached on 30 September 2023.ALNY Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$188.13 M
-$290.77 M-283.29%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM operating income is currently -$188.13 million, with the most recent change of -$290.77 million (-283.29%) on 30 September 2024. Over the past year, it has increased by +$166.25 million (+46.91%). ALNY TTM operating profit is now -283.29% below its all-time high of $102.64 million, reached on 30 June 2024.ALNY TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.1% | -136.0% | +46.9% |
| 3 y3 years | +65.9% | +57.7% | +73.4% |
| 5 y5 years | +65.4% | +64.5% | +78.2% |
ALNY Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +65.9% | -136.0% | +70.2% | -283.3% | +77.2% |
| 5 y | 5 years | at high | +70.0% | -136.0% | +74.2% | -283.3% | +80.4% |
| alltime | all time | -6583.4% | +70.0% | -136.0% | +74.2% | -283.3% | +80.4% |
Alnylam Pharmaceuticals Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$76.91 M(-258.2%) | -$188.13 M(-283.3%) |
| June 2024 | - | $48.61 M(-211.9%) | $102.64 M(-158.4%) |
| Mar 2024 | - | -$43.44 M(-62.7%) | -$175.80 M(-37.7%) |
| Dec 2023 | -$282.18 M(-64.1%) | -$116.40 M(-154.4%) | -$282.18 M(-20.4%) |
| Sept 2023 | - | $213.87 M(-193.1%) | -$354.38 M(-57.1%) |
| June 2023 | - | -$229.83 M(+53.4%) | -$826.29 M(+4.8%) |
| Mar 2023 | - | -$149.81 M(-20.6%) | -$788.15 M(+0.4%) |
| Dec 2022 | -$785.07 M(+10.8%) | -$188.61 M(-26.9%) | -$785.07 M(-0.8%) |
| Sept 2022 | - | -$258.04 M(+34.6%) | -$791.02 M(+10.7%) |
| June 2022 | - | -$191.69 M(+30.6%) | -$714.66 M(+6.8%) |
| Mar 2022 | - | -$146.73 M(-24.6%) | -$669.13 M(-5.6%) |
| Dec 2021 | -$708.65 M(-14.5%) | -$194.56 M(+7.1%) | -$708.65 M(+0.0%) |
| Sept 2021 | - | -$181.68 M(+24.3%) | -$708.31 M(-5.8%) |
| June 2021 | - | -$146.16 M(-21.5%) | -$751.84 M(-6.6%) |
| Mar 2021 | - | -$186.25 M(-4.1%) | -$804.53 M(-2.9%) |
| Dec 2020 | -$828.44 M(-11.8%) | -$194.22 M(-13.8%) | -$828.44 M(-11.1%) |
| Sept 2020 | - | -$225.20 M(+13.2%) | -$932.29 M(+1.0%) |
| June 2020 | - | -$198.86 M(-5.4%) | -$923.39 M(-3.9%) |
| Mar 2020 | - | -$210.16 M(-29.5%) | -$960.80 M(+2.3%) |
| Dec 2019 | -$939.43 M(+15.3%) | -$298.07 M(+37.8%) | -$939.43 M(+9.0%) |
| Sept 2019 | - | -$216.30 M(-8.5%) | -$861.71 M(-4.3%) |
| June 2019 | - | -$236.27 M(+25.2%) | -$899.97 M(+5.1%) |
| Mar 2019 | - | -$188.79 M(-14.3%) | -$856.06 M(+5.1%) |
| Dec 2018 | -$814.67 M(+62.9%) | -$220.36 M(-13.4%) | -$814.67 M(+9.9%) |
| Sept 2018 | - | -$254.56 M(+32.3%) | -$741.62 M(+21.0%) |
| June 2018 | - | -$192.35 M(+30.5%) | -$612.86 M(+13.3%) |
| Mar 2018 | - | -$147.41 M(+0.1%) | -$540.98 M(+8.2%) |
| Dec 2017 | -$500.09 M(+17.8%) | -$147.30 M(+17.1%) | -$500.09 M(+6.8%) |
| Sept 2017 | - | -$125.80 M(+4.4%) | -$468.22 M(+4.3%) |
| June 2017 | - | -$120.47 M(+13.1%) | -$449.09 M(+6.7%) |
| Mar 2017 | - | -$106.51 M(-7.7%) | -$421.07 M(-0.8%) |
| Dec 2016 | -$424.59 M(+43.4%) | -$115.43 M(+8.2%) | -$424.59 M(+5.7%) |
| Sept 2016 | - | -$106.68 M(+15.4%) | -$401.67 M(+7.6%) |
| June 2016 | - | -$92.45 M(-16.0%) | -$373.32 M(+5.5%) |
| Mar 2016 | - | -$110.03 M(+18.9%) | -$353.81 M(+19.5%) |
| Dec 2015 | -$296.01 M(+60.7%) | -$92.51 M(+18.1%) | -$296.01 M(+18.8%) |
| Sept 2015 | - | -$78.33 M(+7.4%) | -$249.21 M(+15.3%) |
| June 2015 | - | -$72.94 M(+39.7%) | -$216.08 M(+12.5%) |
| Mar 2015 | - | -$52.22 M(+14.2%) | -$192.03 M(+4.2%) |
| Dec 2014 | -$184.21 M(+98.2%) | -$45.71 M(+1.1%) | -$184.21 M(+9.6%) |
| Sept 2014 | - | -$45.20 M(-7.6%) | -$168.09 M(+8.4%) |
| June 2014 | - | -$48.90 M(+10.1%) | -$155.13 M(+21.6%) |
| Mar 2014 | - | -$44.41 M(+50.1%) | -$127.55 M(+37.2%) |
| Dec 2013 | -$92.94 M | -$29.59 M(-8.2%) | -$92.94 M(+7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | -$32.23 M(+51.2%) | -$86.70 M(+19.4%) |
| June 2013 | - | -$21.31 M(+117.4%) | -$72.62 M(+14.6%) |
| Mar 2013 | - | -$9.80 M(-58.0%) | -$63.37 M(-0.3%) |
| Dec 2012 | -$63.57 M(+16.0%) | -$23.35 M(+28.7%) | -$63.57 M(+18.2%) |
| Sept 2012 | - | -$18.15 M(+50.4%) | -$53.80 M(+11.9%) |
| June 2012 | - | -$12.07 M(+20.7%) | -$48.09 M(-2.1%) |
| Mar 2012 | - | -$10.00 M(-26.4%) | -$49.14 M(-10.4%) |
| Dec 2011 | -$54.82 M(+25.3%) | -$13.59 M(+9.2%) | -$54.82 M(+2.8%) |
| Sept 2011 | - | -$12.44 M(-5.2%) | -$53.31 M(+7.5%) |
| June 2011 | - | -$13.12 M(-16.3%) | -$49.60 M(+3.1%) |
| Mar 2011 | - | -$15.68 M(+29.8%) | -$48.11 M(+10.0%) |
| Dec 2010 | -$43.74 M(-9.1%) | -$12.08 M(+38.4%) | -$43.74 M(+10.1%) |
| Sept 2010 | - | -$8.73 M(-24.9%) | -$39.73 M(-2.3%) |
| June 2010 | - | -$11.63 M(+2.8%) | -$40.65 M(-21.0%) |
| Mar 2010 | - | -$11.31 M(+40.1%) | -$51.44 M(+6.9%) |
| Dec 2009 | -$48.11 M(+72.8%) | -$8.07 M(-16.4%) | -$48.11 M(+0.5%) |
| Sept 2009 | - | -$9.65 M(-56.9%) | -$47.85 M(+15.5%) |
| June 2009 | - | -$22.41 M(+180.9%) | -$41.44 M(+30.1%) |
| Mar 2009 | - | -$7.98 M(+2.1%) | -$31.86 M(+14.5%) |
| Dec 2008 | -$27.84 M(-70.1%) | -$7.81 M(+141.6%) | -$27.84 M(+21.5%) |
| Sept 2008 | - | -$3.23 M(-74.8%) | -$22.91 M(-67.7%) |
| June 2008 | - | -$12.83 M(+224.3%) | -$71.02 M(-2.9%) |
| Mar 2008 | - | -$3.96 M(+36.8%) | -$73.14 M(-21.5%) |
| Dec 2007 | -$93.18 M(+135.9%) | -$2.89 M(-94.4%) | -$93.18 M(-7.1%) |
| Sept 2007 | - | -$51.34 M(+243.3%) | -$100.28 M(+74.3%) |
| June 2007 | - | -$14.95 M(-37.7%) | -$57.54 M(+7.2%) |
| Mar 2007 | - | -$23.99 M(+140.2%) | -$53.70 M(+35.9%) |
| Dec 2006 | -$39.50 M(-9.1%) | -$9.99 M(+16.1%) | -$39.50 M(-11.1%) |
| Sept 2006 | - | -$8.60 M(-22.5%) | -$44.43 M(-4.4%) |
| June 2006 | - | -$11.11 M(+13.4%) | -$46.49 M(-0.2%) |
| Mar 2006 | - | -$9.80 M(-34.3%) | -$46.59 M(+7.2%) |
| Dec 2005 | -$43.47 M(+34.7%) | -$14.92 M(+39.8%) | -$43.47 M(+27.5%) |
| Sept 2005 | - | -$10.67 M(-4.8%) | -$34.09 M(+14.2%) |
| June 2005 | - | -$11.20 M(+67.7%) | -$29.84 M(+16.5%) |
| Mar 2005 | - | -$6.68 M(+20.8%) | -$25.61 M(-20.6%) |
| Dec 2004 | -$32.26 M(+57.8%) | -$5.53 M(-13.9%) | -$32.26 M(-31.8%) |
| Sept 2004 | - | -$6.43 M(-7.9%) | -$47.31 M(+15.8%) |
| June 2004 | - | -$6.97 M(-47.7%) | -$40.84 M(+14.6%) |
| Mar 2004 | - | -$13.33 M(-35.2%) | -$35.65 M(+51.2%) |
| Dec 2003 | -$20.45 M(+384.3%) | -$20.58 M(<-9900.0%) | -$23.59 M(+684.6%) |
| Sept 2003 | - | $44.00 K(-102.5%) | -$3.01 M(-1.4%) |
| June 2003 | - | -$1.78 M(+40.9%) | -$3.05 M(+140.9%) |
| Mar 2003 | - | -$1.27 M | -$1.27 M |
| Dec 2002 | -$4.22 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual operaing income?
- What is the all time high annual operating profit for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual operating profit year-on-year change?
- What is Alnylam Pharmaceuticals quarterly operating income?
- What is the all time high quarterly operating profit for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly operating profit year-on-year change?
- What is Alnylam Pharmaceuticals TTM operating income?
- What is the all time high TTM operating profit for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM operating profit year-on-year change?
What is Alnylam Pharmaceuticals annual operaing income?
The current annual operating profit of ALNY is -$282.18 M
What is the all time high annual operating profit for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual operaing income is -$4.22 M
What is Alnylam Pharmaceuticals annual operating profit year-on-year change?
Over the past year, ALNY annual operaing income has changed by +$502.90 M (+64.06%)
What is Alnylam Pharmaceuticals quarterly operating income?
The current quarterly operating profit of ALNY is -$76.91 M
What is the all time high quarterly operating profit for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly operating income is $213.87 M
What is Alnylam Pharmaceuticals quarterly operating profit year-on-year change?
Over the past year, ALNY quarterly operating income has changed by -$290.77 M (-135.96%)
What is Alnylam Pharmaceuticals TTM operating income?
The current TTM operating profit of ALNY is -$188.13 M
What is the all time high TTM operating profit for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM operating income is $102.64 M
What is Alnylam Pharmaceuticals TTM operating profit year-on-year change?
Over the past year, ALNY TTM operating income has changed by +$166.25 M (+46.91%)